Do you want to remove all your recent searches?

All recent searches will be deleted

Watch Later
Add to

Howard Hutchinson, MD, Chief Medical Officer, AstraZeneca

8 years ago257 views



CRESTOR™ (rosuvastatin) has been approved in nineteen countries within the EU for the prevention of major cardiovascular events in patients who are at high risk of having a first cardiovascular event. This new indication is based on subgroup data from the landmark JUPITER study, which evaluated the impact of rosuvastatin 20 mg on reducing major cardiovascular events in a previously unstudied population. A post-hoc analysis of this subgroup data showed a significant reduction in the combined endpoint of heart attacks, strokes and CV deaths amongst the high risk patients within JUPITER. To view Multimedia News Release, go to

Report this video

Select an issue

Embed the video

Howard Hutchinson, MD, Chief Medical Officer, AstraZeneca
<iframe frameborder="0" width="480" height="270" src="//" allowfullscreen allow="autoplay"></iframe>
Add the video to your site with the embed code above